April 2013
Physician Assistants' Prescribing Reference;Spring2013, Vol. 20 Issue 1, pA18
The article offers medical news briefs for development in products and systems. It reports that albuterol sulfate inhalation aeroso ProAir HFA by pharmaceutical company Teva is available with a dose counter. It announces that sumatriptan iontophoretic transdermal system Zecuity by pharmaceutical company NuPathe and Prevnar 13, pneumococcal 13-valent conjugate vaccine, have been approved by Food and Drug Administration (FDA).


Related Articles

  • GENERICS NEWSLINE.  // Physician Assistants' Prescribing Reference;Winter2012, Vol. 19 Issue 4, pA-14 

    The article offers news updates on generic pharmaceutical products. It informs about the approval of Watson's Trospium Chloride Extended-Release Capsule, a generic for Sanctura XR antispasmodic; launch of Ranbaxy's Cevimeline HCl Capsules, the generic version of Daiichi Sankyo’s Evoxac...

  • GENERICS NEWSLINE.  // Nurse Practitioners Prescribing Reference;Winter2012, Vol. 19 Issue 4, pA-14 

    The article offers generic product news briefs as of November, 2012. Nicotine Polacrilex Mini Lozenge, the generic version of GlaxoSmithKline’s Nicorette Mini Lozenge will be marketed over-the-counter by Perrigo. Methylphenidate HCl Extended-Release Capsules, which are the generic version...

  • Clip & Save: Drug Chart.  // Journal of Psychosocial Nursing & Mental Health Services;Jan2013, Vol. 51 Issue 1, following p47 

    No abstract available.

  • Targeting the incretin system: Novel advances in the treatment of diabetes. Williams, Kristal L.; Prasad-Reddy, Lalita // Formulary;Sep2012, Vol. 47 Issue 9, p330 

    Type 2 diabetes mellitus remains a complex and prevalent disease in the United States today. Therapies including sulfonylureas and thiazolidinediones have been effective in its management but their limits in the long term are problematic. Incretin-based therapies are now the most promising...

  • FDA actions in brief.  // Formulary;May2008, Vol. 43 Issue 5, p156 

    The article focuses on the actions taken by the U.S. Food and Drug Administration to approved various drugs. Janumet, a sitagliptin/metformin, from Merck is approved to improve glycemic control in adults with type 2 diabetes. The changes in labeling for Schering-Plough Corp.'s Pegintron and...

  • JUVISYNC.  // Nurse Practitioners Prescribing Reference;Spring2012, Vol. 19 Issue 1, pA-12 

    The article offers brief information on Juvisync drug for diabetes and cholesterol treatment from Merck.

  • Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy. Ahn, James; Ahn, Hyung Seok; Cheong, Jae Hoon; dela Peña, Ike // Neural Plasticity;2/4/2016, p1 

    Typical treatment plans for attention-deficit/hyperactivity disorder (ADHD) utilize nonpharmacological (behavioral/psychosocial) and/or pharmacological interventions. Limited accessibility to behavioral therapies and concerns over adverse effects of pharmacological treatments prompted research...

  • Repaglinide/Troglitazone Combination Therapy. Raskin, Philip; Jovanovic, Lois; Berger, Sheldon; Schwartz, Sherwyn; Woo, Vincent; Ratner, Robert // Diabetes Care;Jul2000, Vol. 23 Issue 7, p979 

    Focuses on a study which compared the efficacy and safety of repaglinide and troglitazone combination therapy, repaglinide monotherapy, and troglitazone monotherapy in type 2 diabetes. Discussions on the pathogenesis of type 2 diabetes; Research design and methods; Conclusions.

  • What's the latest on sulphonylureas in the management of type 2 diabetes? Mkele, Gail // South African Family Practice;Nov/Dec2013, Vol. 55 Issue 6, p501 

    Sulphonylureas act by binding to sulphonylurea receptors and stimulating insulin secretion from pancreatic beta cells. This class of oral hypoglycaemic agents is still widely used in the management of type 2 diabetes in patients where lifestyle changes alone are insufficient. Although the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics